LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a revised preliminary non-binding proposal letter (the "Revised Proposal Letter"), dated August 26, 2025, from a consortium (the "Consortium") comprised of Oceanpine Investment Fund II LP and Oceanpine Capital Inc. (together, "Oceanpine Capital"), and Crystal Peak Investment Inc. to acquire all of the outstanding ordinary shares, par value US$0.0002 per share, of the Company (the "Ordinary Shares") that are not currently owned by the Consortium in an all-cash transaction for US$0.86 per Ordinary Share, which remains unchanged from the original proposal (the "Proposed Transaction").

Read more at prnewswire.com